Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Otsuka Canada Pharmaceutical Inc. (Canada)
Homepage:
otsukacanada.com
Alternate names:
Otsuka Canada Pharmaceutical,
Otsuka Canada Pharmaceutique
ROR:
0453abt59
OpenAlex ID:
I4405272422
Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy
2015
·
Ahsan Alam
, Neera K. Dahl
, et al.
·
American Journal of Kidney Diseases
·
69
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study
2019
·
Sally Mustafa
, Joanna Bougie
, et al.
·
BMC Psychiatry
·
33
PDF
Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma
2013
·
Donna Reece
, Kevin Song
, et al.
·
The Oncologist
·
27
Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores
2017
·
Zahinoor Ismail
, Timothy Peters-Strickland
, et al.
·
Journal of Clinical Psychopharmacology
·
15
Role of serotonin in psychiatric and somatic comorbidities of attention-deficit/hyperactivity disorder: a systematic literature review
2025
·
Stephen V. Faraone
, Caroline L. Ward
, et al.
·
Neuroscience & Biobehavioral Reviews
·
13
Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
2022
·
Christoph U. Correll
, Ying He
, et al.
·
The Journal of Clinical Psychiatry
·
13
PDF
Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies
2022
·
Martin A. Katzman
, François Therrien
, et al.
·
Journal of Affective Disorders
·
12
PDF
The Symptoms Targeted for Monitoring in a Web-Based Tracking Tool by Caregivers of People With Dementia and Agitation: Cross-Sectional Study
2019
·
Kenneth Rockwood
, Myrlene Sanon Aigbogun
, et al.
·
Journal of Medical Internet Research
·
12
PDF
Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled Studies
2024
·
Roger S. McIntyre
, Suzy Bubolic
, et al.
·
Journal of Clinical Psychopharmacology
·
11
Exploring life engagement from the perspective of patients with major depressive disorder: a study using patient interviews
2022
·
François Therrien
, Stine R. Meehan
, et al.
·
Journal of Patient-Reported Outcomes
·
11
PDF
Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
2022
·
Daniel Schöttle
, Guerline Clerzius
, et al.
·
European Psychiatry
·
11
PDF
Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data
2023
·
Roger S. McIntyre
, François Therrien
, et al.
·
Journal of Psychiatric Research
·
10
Role of serotonin in the neurobiology of attention-deficit/hyperactivity disorder: a systematic literature review
2025
·
Stephen V. Faraone
, Caroline L. Ward
, et al.
·
Expert Opinion on Therapeutic Targets
·
9
PDF
Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4
2024
·
François Therrien
, Caroline Ward
, et al.
·
The Canadian Journal of Psychiatry
·
9
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
2023
·
Oloruntoba Oluboka
, Guerline Clerzius
, et al.
·
BMC Psychiatry
·
9
PDF
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
2022
·
Howard C. Margolese
, Matthieu Boucher
, et al.
·
BMC Psychiatry
·
7
PDF
Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
2022
·
Derek Pinnell
, Shardool Patel
, et al.
·
Medicine
·
6
Urgency to treat and early optimized treatment in major depressive disorder: consequences of delayed treatment, barriers to implementation, and practical strategies for clinicians
2025
·
Oloruntoba J. Oluboka
, Jeffrey Habert
, et al.
·
CNS Spectrums
·
3
PDF
EE519 Cost Effectiveness Analysis of Avacopan in Antineutrophil Cytoplasm Antibody-Associated Vasculitis - A Canadian Perspective
2022
·
K Lakhdari
, C Vicente
, et al.
·
Value in Health
·
3
Impact of Initiation of Long-Acting Injectable Antipsychotics on Resource Utilization In Patients with Schizophrenia
2016
·
J Lachaine
, M Larbi
, et al.
·
Value in Health
·
3
Long-Term Experience of Tolvaptan: Is Hepatotoxicity Still a Concern?
2025
·
Pierre Antoine Brown
, Suzy Bubolic
, et al.
·
Kidney360
·
2
Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study
2024
·
Marc-André Roy
, François Therrien
, et al.
·
BMC Psychiatry
·
2
PDF
BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)
2023
·
Daniel Schöttle
, Wolfgang Janetzky
, et al.
·
BMC Psychiatry
·
2
PDF
Pos-337 Canadian Real-world Assesment of Tolvaptan in Adpkd: C-major Study and Safety Monitoring and Distribution Program
2021
·
P. McFarlane
, P. Parfrey
, et al.
·
Kidney International Reports
·
2
PDF
Treatment patterns of agitation associated with Alzheimer’s dementia (AAD) patients in Canada
2026
·
Veronique Littmann-Crites
, A. Marilise Marrache
, et al.
·
International Psychogeriatrics
·
1
Show more works
View as search
Works count:
46
Citation count:
498
Year
Topic
Type
